Author

K. D. Malone

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Approach:statistical model· 1

Frequent Co-Authors

J. D. Bloom· 5 shared A. J. Greaney· 3 shared A. N. Loes· 3 shared H. Y. Chu· 3 shared T. N. Starr· 3 shared D. Pettie· 2 shared D. Veesler· 2 shared K. H. Crawford· 2 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

J. D. Bloom

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Stabilization of the SARS-CoV-2 Spike receptor-binding domain using deep mutational scanning and structure-based design

D. Ellis, N. Brunette, K. H. D. Crawford, A. C. Walls, M. N. Pham, C. Chen, K.-L. Herpoldt, B. Fiala, M. Murphy, D. Pettie, J. C. Kraft, K. D. Malone, M. J. Navarro, C. Ogohara, E. Kepl, , N. P. King

This paper designs stabilized SARS-CoV-2 RBD variants using deep mutational scanning and structure-based design, showing improved thermal stability and manufacturability for vaccine applications.

bioRxiv · May 15, 2021Microbiology

Comprehensive profiling of mutations to influenza virus PB2 that confer resistance to the cap-binding inhibitor pimodivir

Y. Q. S. Soh, K. D. Malone, R. T. Eguia, J. D. Bloom

This study maps all single-amino-acid mutations in avian PB2 conferring resistance to pimodivir, identifying known and novel mutations in multiple domains.

bioRxiv · May 11, 2021Microbiology

The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD

A. J. Greaney, A. N. Loes, L. E. Gentles, K. H. Crawford, T. N. Starr, K. D. Malone, H. Y. Chu, J. D. Bloom

The paper compares the specificity of antibodies from the mRNA-1273 vaccine and natural infection, finding vaccine antibodies are more RBD-focused but have broader epitope coverage within the RBD.

bioRxiv · Apr 14, 2021Microbiology

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

A. J. Greaney, A. N. Loes, K. H. Crawford, T. N. Starr, K. D. Malone, H. Y. Chu, J. D. Bloom

This study maps mutations in the SARS-CoV-2 RBD that affect recognition by polyclonal human serum antibodies, identifying key sites like E484 that significantly reduce neutralization.

bioRxiv · Dec 31, 2020Microbiology

Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays

K. H. D. Crawford, R. Eguia, A. S. Dingens, A. N. Loes, K. D. Malone, C. R. Wolf, H. Y. Chu, M. A. Tortorici, D. Veesler, M. Murphy, D. Pettie, N. P. King, A. B. Balazs, J. D. Bloom

This paper provides a protocol for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein to measure neutralizing antibody activity in a luciferase-based assay.

bioRxiv · Apr 20, 2020Microbiology